Chimeric VSV-MorV-G for Oncolysis With Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapeutics and radiation therapy, are often ineffective against advanced cancer, and traditional oncolytic viruses like wild type VSV can cause neurotoxicity and liver toxicity, as well as induce encephalitis in humans.
Innovation Solution
Development of chimeric vesiculoviruses, specifically VSV-MorV-G, which express the G polypeptide of MorV and lack the VSV G polypeptide, maintaining a fast lytic cycle while being resistant to VSV neutralizing antibodies and inducing oncolysis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild type VSV is used for oncolytic virotherapy, then fast lytic cycle and broad mammalian cellular tropism are achieved, but neurotoxicity and liver toxicity occur
Solution Approach 1:
The patent extracts and removes the harmful G protein gene from the VSV genome, replacing it with a deleted version that cannot produce functional G protein. This extraction of the toxic element maintains the fast lytic cycle capability while eliminating neurotoxicity and liver toxicity, as the essential viral functions are preserved through other genomic components.
Solution Approach 2:
The patent changes the genetic parameter of the G protein by introducing deletions or mutations in the G gene sequence. This parameter modification transforms the G protein from a toxic form to a non-toxic or reduced-toxic form, thereby reducing harmful effects while preserving the viral oncolytic activity and lytic cycle speed.
2Productivity
If wild type VSV is used for oncolytic virotherapy, then potent cancer cell lysis is achieved, but VSV neutralizing antibodies are induced
Solution Approach 1:
The patent changes the antigenic parameters of the viral surface proteins by modifying the G protein sequence through deletions or mutations. This parameter change alters the epitopes recognized by neutralizing antibodies, allowing the virus to maintain its cancer cell lysis efficiency while evading pre-existing or induced neutralizing antibody responses.
3Ease of operation
If traditional cancer therapies are used, then treatment simplicity is maintained, but effectiveness against advanced cancer is insufficient
Solution Approach 1:
The patent employs oncolytic viruses that perform self-service by autonomously replicating within and destroying cancer cells. The viral system self-propagates and self-amplifies at the tumor site, eliminating the need for repeated administrations or complex combination protocols, thereby maintaining treatment simplicity while achieving superior effectiveness against advanced cancer compared to traditional therapies.
Data Source
Figure 1
Figure 2
Figure 2
AI summary
This document provides methods and materials for treating cancer. For example, chimeric vesiculoviruses (e.g., chimeric vesicular stomatitis viruses (VS Vs)) and methods for using such chimeric vesiculoviruses as an oncolytic agent (e.g., to treat cancer) are provided.